10 research outputs found
Sociodemographic and virological characteristics and comedications used, by severity of liver disease, among HCV-infected patients undergoing DAA therapy.
<p>Sociodemographic and virological characteristics and comedications used, by severity of liver disease, among HCV-infected patients undergoing DAA therapy.</p
Drug classes used as comedication when beginning DAA therapy, by severity of liver disease, among HCV-infected patients.
<p>Drug classes used as comedication when beginning DAA therapy, by severity of liver disease, among HCV-infected patients.</p
Number of co-medications used and percentage of patients, by DAA regimen, among HCV-infected patients.
<p>(A) Patients with mild liver disease. (B) Patients with moderate-to severe-liver disease. SOF/RBV: sofosbuvir plus ribavirin, SOF/SIM: sofosbuvir plus simeprevir, SOF/DCV: sofosbuvir plus daclatasvir, SOF/LDV: sofosbuvir plus ledipasvir, 3D: paritaprevir/ritonavir, ombitasvir, dasabuvir. The percentage of patients who took one drug (in blu), two drugs (in red), three drugs (in green) and more than 3 drugs (in violet) are reported considering the total number of patients reported for each regimen in both Fig 1A and Fig 1B at the same manner.</p
Category of potential DDIs, by DAA regimen and severity of liver disease, among HCV-infected patients.
<p>Comedication used in patients with mild liver disease (A) or in (B) patients with moderate-to severe-liver disease (B). DAA regiments and number of comedications used are shown. SOF/RBV: sofosbuvir plus ribavirin, SOF/SIM: sofosbuvir plus simeprevir, SOF/DCV: sofosbuvir plus daclatasvir, SOF/LDV: sofosbuvir plus ledipasvir, 3D: paritaprevir/ritonavir, ombitasvir, dasabuvir. Category 0: Classification not possible due to lack of information; Category 1: No clinical interaction possible; Category 2: May require dose adjustment/closer monitoring.</p
The most common drugs with a potential DDI among HCV-infected patients with moderate-to-severe liver disease.
<p>The most common drugs with a potential DDI among HCV-infected patients with moderate-to-severe liver disease.</p
Population kinetic parameters for the best HCV and ALT kinetic model.
<p>Population kinetic parameters for the best HCV and ALT kinetic model.</p
Decrease of viral load and ALT at different time points under treatment according to NS5A-inhibitors and interferon administration.
<p>These graphs shows the median of predictions of ALT and HCV-RNA in different groups of treatment obtained by simulations from the parameter estimates of the two models. ALT, alanine transaminase; IFN, interferon.</p
Predicted kinetic profiles obtained by simulations from the viral and ALT kinetic models.
<p>(panel <b>A</b>) Different viral kinetics according to HCV-genotypes, NS5A-inhibitors and interferon administration, (panel <b>B</b>) Different ALT kinetics according to NS5A-inhibitors and interferon administration. ALT, alanine transaminase; IFN, interferon.</p
Biphasic kinetics of HCV-RNA decay, and ALT drop during all-DAA and TVR+PR treatment and follow-up.
<p>In <i>upper panels</i>, median values with 95% confidence interval of HCV-RNA (black dots) and ALT (grey squares) during all-DAAs (panel <b>A</b>) and TVR+PR (panel <b>B</b>) treatment are reported. End of follow-up is at 12 weeks after treatment discontinuation. Black dotted line represents the lower limit of detection of HCV-RNA (12–15 IU/ml). Grey dotted line represents normality range of ALT values in females (45 IU/ml). Histograms in <i>lower panels</i> represent the percentages of patients with HCV-RNA below the lower limit of detection (panel <b>C</b>) and with normal ALT values (panel <b>D</b>) during all-DAAs (black) and TVR+PR (grey) treatment. Normal ALT values were considered as <55 IU/ml in men, and <45 IU/ml in women. ALT, alanine transaminase; DAA, direct-acting antivirals; EOT, end of treatment; IU, international units; LLOD, lower limit of detection (<12–15 IU/ml, not detected); PR, pegylated interferon and ribavirin; TVR, telaprevir. * p-value <0.05 by Fisher exact test; ** p-value ≤0.001 by Fisher exact test.</p
Cox analysis for factors influencing ALT normalization during treatment.
<p>Cox analysis for factors influencing ALT normalization during treatment.</p